The Y-90 resin microspheres demonstrated a 98.5% best overall objective response rate, with all patients responding to the treatment.

III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment.

KRd as a potential standard-of-care regimen in this hard-to-treat population of high-risk, newly diagnosed multiple myeloma,” said Lisa B. Leypoldt, MD.

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

In her presentation at AANP 2025, Dr Haylei Lorca includes case studies of 3 patients who present with atypical psychiatric symptoms.

Researchers analyzed SOGI data collection practices to determine the factors associated with its prevalence across cancer centers by type and geographic area.

Investigators examined survival outcomes and recurrence patterns by pathologic nodal status in patients with upper tract urothelial carcinoma (UTUC) receiving neoadjuvant chemotherapy.

The albumin-bilirubin (ALBI) score can independently predict prognosis in post-surgical patients with distal cholangiocarcinoma (dCCA), a form of cholangiocarcinoma (CCA), according to results ...

A distinct natural killer (NK) cell subset, termed CLL_NK, is a precursor to effector NK phenotypes and serves as a critical immunologic marker in chronic lymphocytic leukemia (CLL), offering ...

Researchers conducted a retrospective cohort study to assess the predictive value of molecular profiling on thyroid tumor behavior.